CYP3A Mediated Ketamine Metabolism is Severely Impaired in Liver S9 Fractions from Aging Sprague Dawley Rats

Raphaël Santamaria¹, Marie-Chantal Giroux², Pascal Vachon^{2,3} and Francis Beaudry¹

1 Groupe de Recherche en Pharmacologie Animal du Québec (GREPAQ), Département de Biomédecine Vétérinaire, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Québec, Canada

² Département de Biomédecine Vétérinaire, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Québec, Canada

³ Centre de Recherche du CHU Sainte-Justine, Montréal, Québec, Canada

* Corresponding author:

Francis Beaudry, Ph.D. Associate Professor in analytical pharmacology Département de Biomédecine Vétérinaire Faculté de Médecine Vétérinaire Université de Montréal 3200 Sicotte Saint-Hyacinthe, QC Canada J2S 2M2

Email: francis.beaudry@umontreal.ca

Tel (514) 343-6111 ext. 8647

Keywords: Ketamine, Geriatrics, Midazolam, Cytochrome P450, Michaelis-Menten, Drug Metabolism, Liquid Chromatography Tandem Mass Spectrometry

Abstract

Ketamine is widely used in veterinary medicine and in medicine. Ketamine is metabolized to its active metabolite norketamine principally by liver CYP3A. Drug metabolism alterations during aging have severe consequences particularly in anesthesiology and very few studies on older animals were conducted for ketamine. The objective of the present study is to assess the influence of aging on CYP3A metabolism of ketamine. Liver S9 fractions from 3, 6, 12 and 18 month old male Sprague Dawley rats were prepared and Michaelis-Menten parameters were determined for primary metabolic pathways. The derived maximum enzyme velocity (i.e. V_{max}) suggests a rapid saturation of the CYP3A enzyme active sites in liver S9 fractions of 18-month old rats. Observed Vmax for Liver S9 fractions from 3, 6 and 12 month old male Sprague Dawley rats were 2.39 (± 0.23) , 2.61 (± 0.18) , and 2.07 (± 0.07) respectively compared to 0.68 (± 0.02) for Liver S9 fractions from 18 month old male Sprague Dawley rats. Interestingly, we observed a 6 to 7 fold change in the derived K_m when comparing Liver S9 fractions from 18 month old male Sprague Dawley rats with Liver S9 fractions from younger rats. Our results suggest that rat CYP3A enzyme undergoes conformational changes with age particularly in our geriatric group (e.g. 18 month rats) leading significant decrease in the rate of formation of norketamine. Moreover, our results strongly suggest a severe impairment of CYP3A ketamine mediated metabolism.

Introduction

In recent years, the improvements in medicine, and life style changes, have increased life expectancy and consequently there is a significant increase of geriatric patients needing medical and pharmacological treatments. A very large proportion of marketed drugs were not thoroughly tested in pediatric and geriatric patients and this has led to numerous medical complications [Richardson *et al*., 2014; Crentsil *et al*., 2014; Hines, 2013]. Older patients certainly have more risks of suffering from adverse drug effects which may be associated with a decreased clearance (CL) caused by physiologic changes associated with aging [Meziere *et al*., 2013; Woodhouse & Wynne, 1988]. Additionally, other studies show a significant increase of terminal half-life $(T_{1/2})$ of many drugs related to aging [Iirola *et al*., 2012; Shi and Klotz, 2011] leading to important differences in pharmacokinetic profiles [Veilleux-Lemieux *et al*., 2013]. Pharmacokinetic and drug metabolism alterations during aging have severe consequences particularly in anesthesiology [Meziere *et al*., 2013]. Geriatric surgeries in animal and human are often avoided when possible since adverse effects could lead to serious consequences including death.

Recently, we performed an exhaustive comparison of ketamine and xylazine pharmacokinetics and pharmacodynamics using 3, 6, 12 and 18 month old male Sprague Dawley rats and observed significant differences in drug exposition (AUC), terminal half-life $(T_{1/2})$ and clearance (CL) in 12 and 18 months old rats [Giroux *et al.*, 2015]. Pharmacokinetic parameters $(T_{1/2}$ and AUC) significantly increased and drug CL significantly decreased with aging and these observations correlated with physiological results (anesthesia duration, reflexes, cardiac and respiratory frequencies and oxygen saturation). As shown in Figure 1, ketamine is metabolized primarily by the liver to an active metabolite, norketamine and it is excreted in the urine [Meyer and Fish, 2008]. In our previous study using rat liver S9 fractions and cDNA CYP3A1 and CYP3A2

expressed enzymes, we demonstrated that ketamine is a substrate of CYP3A (i.e. CYP3A1 and CYP3A2) [Santamaria *et al.*, 2014]. The significant increase of $T_{1/2}$ and decrease of CL observed *in vivo* could possibly be associated with hampered CYP450 liver enzymes, which requires further investigation.

The objective of the present study is to assess the influence of aging on CYP3A metabolism of ketamine. Liver S9 fractions from 3, 6, 12 and 18 month old male Sprague Dawley rats were prepared and Michaelis-Menten parameters were determined for primary metabolic pathways. Midazolam, is primarily metabolized in the liver by the CYP3A to its pharmacologic active metabolite, α-hydroxymidazolam [Shimizu *et al*., 2007] and it is a preferred CYP3A substrate extensively used for *in vitro* and *in vivo* studies [Halama *et al*., 2013; Mooiman *et al.*, 2013]. Midazolam was used to verify and validate CYP3A activity in liver S9 fractions prepared from tissues obtained from animals of different age groups. Drug and metabolite analyses were performed using a HPLC-MS/SRM method capable of quantifying norketamine and αhydroxymidazolam using an isotopic dilution strategy in liver S9 fraction suspensions.

Materials and Methods

Chemicals and Reagents

Ketamine, d₄-ketamine, norketamine, d₄-norketamine, midazolam, d₄-midazolam and α hydroxymidazolam and d_4 - α -hydroxymidazolam were obtained in solution from Cerilliant (Round Rock, TX). Other chemicals, including acetonitrile, formic acid, methanol, sodium phosphate dibasic and sodium phosphate monobasic were purchased from Fisher Scientific (Ottawa, ON, Canada). Commercial rat liver S9 fractions and NADPH regeneration solutions were obtained from Corning Gentest (Tewksbury, MA, USA).

Animal study

Twenty-four specific pathogen free male Sprague Dawley rats from Charles River Canada (St-Constant, QC) were used for this study. Seven to nine weeks old rats (n=6/age group) were purchase and kept until they were respectively 3 and 6 months old. Twelve 8 month old rats were purchased and kept until they were 12 and 18 months of age (n=6/age group). All rats were housed in a standard laboratory animal environment. The rats had *ad libidum* access to food (2018 Teklad Global 18 % Protein Rodent Diet, Harlan Teklad, Bartonville, IL) and reverse osmosis water. They were single housed in ventilated cages (Green Line IVC Sealsafe Plus, Tecniplast, USA) changed once a week. Rats were housed on corn cob bedding (7097 corncob, Harlan Teklad, Bartonville, IL) and they had a high temperature polycarbonate rat retreat (Bioserv, Flemington, NJ) and one nylabone (Bioserv, Flemington, NJ) for environmental enrichment. The Institutional Animal Care and Use Committee approved the protocol prior to animal use in agreement with the guidelines of the Canadian Council on Animal Care [Canadian Council on Animal Care, 1993]. Rats were euthanized with $CO₂$, livers were rapidly remove and S9 fractions where prepared.

Rat Liver S9 preparation and incubation

For each age group, three livers were pooled and homogenized in a 50 mM TRIS-HCl buffer, pH 7.4, containing 150 mM KCl and 2 mM EDTA at a ratio of 1:4 (w:v). The homogenates were centrifuged at 9,000 *g* for 20 minutes. The total amount of protein in each supernatant was determined using the standard Coomassie protein assay (Bradford). Supernatant aliquots were kept à -80 °C until usage.

The incubations were performed as previously described [Lavoie *et al*., 2013; Santamaria *et al.* 2014] and were performed minimally in triplicate. The incubations were performed in a microcentrifuge tube and contained various concentrations ranging from 1 to 100 μ M of ketamine or midazolam, 0.5 mg/mL of S9 fraction proteins diluted in 100 mM phosphate buffer, pH 7.4. Liver S9 enzyme suspensions (total volume of 100 μ L) were fortified with 5 μ L of NADPH-regenerating solution A (Corning BD Biosciences Cat. No. 451220) and 1 µL of solution B (Corning BD Biosciences Cat. No. 451200) and preincubated at 37°C for 5 min prior the addition of ketamine or midazolam. For the determination of K_m and V_{max} , the concentration of norketamine or α-hydroxymidazolam was determined after 10 min incubation to calculate the initial rate of formation (i.e. V_i). Fifty μ L of samples were taken and mixed with 250 μ L of the deuterated internal standard solution (1 μ M d₄-norketamine or d₄- α -hydroxymidazolam in acetonitrile) in a 1.5 mL centrifuge tube. Samples were centrifuged at 12,000 *g* for 10 min and 200 µL of the supernatant was transferred into an injection vial for HPLC-MS/SRM analysis.

Quantitative Analytical Methods

The concentrations of norketamine and α-hydroxymidazolam were determined using an HPLC-MS/SRM assay. Two µL samples were injected using a Thermo Scientific Accela HPLC System (San Jose, CA, USA) onto a Thermo Hypersil Phenyl 100 x 2 mm column (5µm) with flow rate of 300 µL/min. The mobile phase consisted of a mixture of acetonitrile, methanol, water and formic acid at a ratio of 60:20:20:0.1, respectively. The Thermo Scientific linear ion trap mass spectrometer (Thermo LTQ-XL) was interfaced with the HPLC system using a pneumatic assisted electrospray ion source. The mass spectrometer was coupled with the HPLC system using a pneumatically assisted electrospray ion source (ESI). The sheath gas was set to 25 units and the ESI electrode was set to 4000 V in positive mode. The capillary temperature was set at

300 \degree C, the capillary voltage to 15 V and the collision energy was set to 40%. All scan events were acquired with a 100 msec maximum injection time. Metabolites and corresponding deuterium-labeled molecule analogues were analyzed in full scan MS/MS and the quantification was based on specific post-processing SRM extracted ion chromatograms. The selected reaction monitoring (SRM) transitions were set to m/z 224.1 \rightarrow 179.0, 228.1 \rightarrow 183.0, 342.1 \rightarrow 297.0 and 346.1 \rightarrow 301.0 for norketamine, d₄-norketamine, α-hydroxymidazolam and d₄-αhydroxymidazolam respectively. The analytical range used was ranging from 0.05μ M to 50 μ M.

Data analysis and regression

All non-linear regression analyses were performed with PRISM (6.0f) GraphPad software (La Jolla, CA) using the non-linear curve-fitting module with an estimation of the goodness of fit. The Michaelis-Menten equation describes the rates of irreversible enzymatic reactions that are generally observed for CYP mediated metabolic reactions. Michaelis-Menten parameters can be estimated with non-linear regression analysis using the Michaelis-Menten equation [Michaelis and Menten, 1913].

$$
v_i = \frac{v_{max}\left[S\right]}{K_m + \left[S\right]}(1)
$$

Were the initial velocity (v_i) was determined using equation 2.

$$
v_i = \frac{d[P]}{dt} = \frac{[\alpha - \text{hydroxymidazolam}]_{10 \text{ min}}}{10 \text{ min}} \text{ or } \frac{[\text{norketamine}]_{10 \text{ min}}}{10 \text{ min}} (2)
$$

The initial rate (v_i) was calculated based on the concentration of norketamine or α hydroxymidazolam measured after a 10 minutes incubation of ketamine or midazolam in rat liver S9 enzyme suspensions. Additionally, the enzyme-mediated clearance (CLu_{int}) that would occur

without physiological limitations including protein binding or hepatic blood flow was determined using equation (5).

$$
CLu_{int} = \frac{V_{max}}{K_m}(5)
$$

Statistical analysis

Results are presented as means $(\pm SD)$. The statistical difference was assessed with a one-way ANOVA and a Tukey's multiple comparisons test using GraphPad PRISM (version 6.0f); $p <$ 0.05 was considered significant.

Results and Discussion

In our previous study, an intraperitoneal administration of ketamine (80 mg/kg) and xylazine (10 mg/kg) in male Sprague Dawley rats of 3, 6, 12 and 18 months of age (n=6/age group) caused a significant increase of the AUC_{0-t} and $AUC_{0-\infty}$ with aging [Giroux *et al.*, 2015]. Compared to 3 month old rats, the ketamine exposure (AUC_{0-t}) increased up to a factor of 4.15 compared with 18 month old rats. The elimination half-life $(T_{1/2})$ and relative clearance (CL/F) significantly decreased with aging. The decrease in $T_{1/2}$ and CL/F might be explained by an age-associated reduction in renal function or an increase in volume of distribution of lipid soluble drugs resulting in a prolongation of $T_{1/2}$ but we can't exclude hepatic clearance impairments. Ketamine is metabolized primarily by the liver CYP3A [Santamaria *et al.*, 2014; Mössner *et al*. 2011] (i.e. CYP3A1 and CYP3A2) to its active metabolite norketamine. Alterations in liver metabolism (e.g. hepatic clearance) with aging could explain the higher AUC observed in the aging rats. Moreover, selected organs, including liver, were taken for histopathology to confirm tissue integrity with aging.

The effect of substrate concentration on the initial rate (V_i) of an enzyme-catalyzed reaction is a fundamental concept in enzyme kinetics. K_m is an indicator of the affinity that an enzyme has for a particular substrate, hence the thermodynamic stability of the enzyme-substrate complex. The stability of the enzyme-substrate complex is closely related to primary, secondary and tertiary structures of the enzyme. It plays a central role in defining the energetically favored binding cluster of the substrate into the active enzyme site [Sun and Scott, 2010]. As shown *in silico*, the structure of the binding cluster may lead to different metabolites or affect the rate of formation [Sun and Scott, 2010]. To adequately determine the value of the apparent Michaelis-Menten constant K_m as well as the maximum rate achieved by the system (V_{max}) , the data were fitted with the Michaelis-Menten equation (1). The initial rate (V_i) was calculated using the equation (2) and concentrations of α-hydroxymidazolam or norketamine were determined after 10 min midazolam or ketamine incubation in rat liver S9 fraction suspensions by HPLC-MS/SRM. Figure 2 shows results coherent with a kinetics following a Michaelis-Menten enzymatic reaction for all rat liver S9 fractions from all age groups and data were compatible with commercial rat liver S9 fractions (data not shown). The derived data are presented in Table 1. Midazolam is a well-characterized substrate of CYP3A and the primary biotransformation product is α -hydroxymidazolam. As illustrated in Table 1 and Figure 2, the observed K_m values were not significantly different when comparing age groups. This is interesting because it suggest that enzyme-substrate complex structure was not significantly different between midazolam and CYP3A (i.e. CYP3A1 and CYP3A2) with age. However, the derived V_{max} suggest a rapid saturation of the CYP3A enzyme active sites in liver S9 fractions of 18-month old rats, thus affecting significantly the intrinsic clearance (CLu_{int}) of the drug. Interestingly for ketamine, the derived K_m value significantly changed in geriatric rats. This observation is very distinctive compared to rat liver CYP3A mediated metabolism of midazolam. The K_m value is directly related to the thermodynamic

stability of the binding cluster of ketamine in the active site of CYP3A. The data indicates a significant decrease of K_m in liver S9 fractions of 18-month old rats and suggest that ketamine may have stronger interactions with CYP3A active site residues leading to a more thermodynamically stable enzyme-substrate complex. However it may also suggest that the enzyme binds the substrate more tightly and consequently necessitates more energy to form the activated transition state complex (EX^{\dagger}) , a necessary intermediate to form the enzyme-product complex (EP) as shown in Equation 6.

$$
E + S \Longleftrightarrow ES \Longleftrightarrow EX^* \Longleftrightarrow EP \Longleftrightarrow E + P \qquad (6)
$$

Free energy difference associated with the formation of the enzyme-substrate complex $(\Delta G_{\text{binding}})$ can have a significant impact on the observed K_m but an increase of the ΔG^{\ddagger} (difference of free energy between EX^{\ddagger} and ES) can also significantly decrease the rate constant k_{cat} (i.e. turnover number) witch represents the number of substrate molecules each enzyme site can convert to a metabolite per unit of time. The rate constant k_{cat} can be related to V_{max} using the Equation 7.

$$
V_{max} = k_{cat} \times [E_{total}] \tag{7}
$$

As illustrated in Figure 2 and in Table 1, derived V_{max} values shows significant differences with age specifically when comparing with results obtain from liver S9 fractions of 18-month old rats. A decrease of V_{max} suggest a rapid saturation of the CYP3A enzyme active sites similar to what has been observed with the reference CYP3A substrate midazolam. These results are therefore compatible with the formation of a more stable enzyme-substrate complex (ES) but a less favorable transition state complex (EX^{\ddagger}) leading to an increase of ΔG^{\ddagger} , thus a decrease of k_{cat} and Vmax. Conformational change of the CYP3A active site with age can potentially explain these results and protein misfolding is characteristic of several age-related problems. The interaction of

the active site residues is substrate dependent and the results appear to suggest that an energetically favored binding cluster of ketamine in the active site of CYP3A is observed with age but interestingly this effect was not observed for midazolam. The formation of a more stable enzyme-substrate complex (ES) may have severe consequences on drug-drug interactions, a major issue in geriatric populations. Equation 5 was used to calculate the CLu_{int} , and the observed CLuint diminishes with aging, associated to the midazolam CYP3A catalyzed reaction, but increases for ketamine (Table 1). When using equation 5, the calculation of CLu_{int} assumes that the concentration of the enzyme catalytic sites remain constant. This assumption cannot be made if conformational changes of the CYP3A active site occurs with aging. Consequently, the CLu_{int} cannot be compared between age groups for the ketamine CYP3A mediated reaction. As shown in Figure 2, the rate of formation of norketamine undergoes a very rapid saturation in the liver S9 fractions of 18-month old rats suggesting that following a relatively high ketamine dose (80 mg/kg), drug metabolism is impaired leading to a significant increase of drug exposition (AUC) and elimination. These results are in accordance with our recent in vivo investigation [Giroux et al., 2015].

Conclusion

Age and related factors have a substantial effect on ketamine bioavailability that can be related to physiological changes but also to liver metabolism alterations. Our results suggest that rat CYP3A enzyme undergoes conformational changes with age particularly in our geriatric group (e.g. 18 month rats) leading to significant decrease in the rate of formation of norketamine. Moreover, results strongly suggest a severe impairment of CYP3A ketamine mediated metabolism.

Acknowledgments

This project was funded by the National Sciences and Engineering Research Council of Canada (F.Beaudry discovery grant no. 386637-2010). The HPLC-MS/MS analyses were performed on instruments funded by the National Sciences and Engineering Research Council of Canada (F.Beaudry Research Tools and Instruments Grants no. 439748-2013). R. Santamaria received a scholarship from *Le Fond du Centenaire* (Faculté de médecine vétérinaire, Université de Montréal). The animal study was funded by CALAM/CALAS (P. Vachon 2014 research fund).

Authorship Contributions

research funding agencies**.**

Each author's contributions to the manuscript are the following; Participated in research design: Santamaria R, Vachon P, Beaudry F Conducted experiments: Santamaria R, Giroux MC, Vachon P, Beaudry F Performed data analysis: Santamaria R, Beaudry F Wrote or contributed to the writing of the manuscript: Santamaria R, Vachon P, Beaudry F All authors: No reported conflicts of interest. The research was funded by recognized Canadian

References

Canadian Council on Animal Care (1993). Guide to the care and use of experimental animals, vol 1, 2nd ed. Ottawa (Canada): Canadian Council on Animal Care

Crentsil V, Lee J, Jackson A (2014). Quantitative drug benefit-risk assessment: utility of modeling and simulation to optimize drug safety in older adults. Ann Pharmacother. 48(3):306- 313.

Giroux MC, Beaudry F, Santamaria R, Hélie P, Burns P, and Vachon P (2015), Physiological, biochemical and pharmacokinetic comparisons between 3, 6, 12 and 18 month old male Sprague Dawley rats following ketamine-xylazine anesthesia, BMC Veterinary Research. MS ID : 9382132761532116. *In Press*

Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE (2013). A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clinical Pharmacology and Therapeutics. 93(6):564-571.

Hines RN (2013). Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm. 452(1-2):3-7.

Iirola T, Ihmsen H, Laitio R, Kentala E, Aantaa R, Kurvinen JP, Scheinin M, Schwilden H, Schüttler J, Olkkola KT. Population pharmacokinetics of dexmedetomidine during long-term sedation in intensive care patients. Br J Anaesth. 108(3):460-468.

Lavoie DS, Pailleux F, Vachon P, Beaudry F (2013). Characterization of xylazine metabolism in rat liver microsomes using liquid chromatography-hybrid triple quadrupole-linear ion trap-mass spectrometry. Biomed Chromatogr. 27(7):882-888

Meyer RE, Fish RE (2008). Pharmacology of injectable anesthetics, sedatives, and tranquilizers, Anesthesia and Analgesia in Laboratory Animals. 2nd ed. San Diego, (CA): Academic Press. p. 27-82.

Meziere A, Paillaud E, Plaud B (2013). Anesthesia in the elderly. Presse Med, 42(2), 197-201.

Michaelis L and Menten ML (1913). *Die Kinetik der Invertinwir*‐ *kung. Biochemische Zeitschrift* 49:334-336.

Mooiman KD, Maas-Bakker RF, Rosing H, Beijnen JH, Schellens JH, Meijerman I (2013). Development and validation of a LC-MS/MS method for the in vitro analysis of 1 hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures. Biomedical Chromatography. 27(9):1107-1116.

Mössner LD, Schmitz A, Theurillat R, Thormann W, Mevissen M (2011). Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans. American Journal of Veterinary Research. 72(11):1505-1513.

Richardson K, Bennett K and Kenny RA (2014). Polypharmacy including falls risk-increasing medications and subsequent falls in community-dwelling middle-aged and older adults. Age Ageing. afu141 (Epub ahead of print)

Santamaria R, Pailleux F, Beaudry F (2014). In vitro ketamine CYP3A-mediated metabolism study using mammalian liver S9 fractions, cDNA expressed enzymes and liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 28(12):1660-1669

Shi S, Klotz U (2011), Age-related changes in pharmacokinetics. Curr Drug Metab. 12(7):601-10.

Shimizu M, Uno T, Tamura HO, Kanazawa H, Murakami I, Sugawara K, Tateishi T (2007). A developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: application of human pharmacokinetic study for measurement of CYP3A activity. Journal of Chromatography B. 847(2):275-281.

Sun H, Scott DO (2010). Structure-based drug metabolism predictions for drug design. Chem Biol Drug Des. 75:3-17

Veilleux-Lemieux D, Castel A, Carrier D, Beaudry F, Vachon P (2013), Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats. J Am Assoc Lab Anim Sci. 52(5):567-70

Table 1. Kinetic parameters associated with the formation α**-hydroxymidazolam and norketamine in liver S9 fractions from aging rats.**

$$
\begin{array}{c}\n^{1,2,} p < 0.001 \\
^{3} p > 0.05 \\
^{4} p < 0.05\n\end{array}
$$

15

Figure legends

Figure 1. Molecular structures of ketamine, norketamine, midazolam and α-hydroxymidazolam

Figure 2. Determination of Michaelis constant K_m and maximum velocity V_{max} using non-linear regression fitting. Each point represents the mean (±SD) of experiments in triplicate. Significant differences of the initial rate of formation (V_i) where observed starting at 5μ M substrate concentration for liver S9 fractions of 18-month old rats.

*** p < 0.05 ** p < 0.01 **** p < 0.0001**

Ketamine

Norketamine

Midazolam

 α -hydroxymidazolam

Figure 2.

